279 related articles for article (PubMed ID: 12841693)
1. A new therapeutical approach: topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy with paclitaxel and platinum.
Sehouli J; Stengel D; Oskay G; Blohmer J; Kaubitzsch S; Lichtenegger W
J Obstet Gynaecol Res; 2003 Jun; 29(3):123-31. PubMed ID: 12841693
[TBL] [Abstract][Full Text] [Related]
2. Dose finding study for combination treatment with topotecan and gemcitabine of patients with recurrent ovarian cancer after failure of first-line chemotherapy with Paclitaxel and platinum.
Sehouli J; Stengel D; Oskay G; Blohmer J; Kaubitzsch S; Lichtenegger W;
Onkologie; 2004 Feb; 27(1):58-64. PubMed ID: 15007250
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy.
Sehouli J; Stengel D; Oskay G; Camara O; Hindenburg HJ; Klare P; Blohmer J; Heinrich G; Elling D; Ledwon P; Lichtenegger W;
Ann Oncol; 2002 Nov; 13(11):1749-55. PubMed ID: 12419747
[TBL] [Abstract][Full Text] [Related]
4. Combination of weekly topotecan and gemcitabine as a salvage treatment in patients with recurrent ovarian cancer: a phase I study.
Syrios J; Kouroussis C; Kotsakis A; Kentepozidis N; Kontopodis E; Kalbakis K; Vardakis N; Hatzidaki D; Polyzos A; Georgoulias V;
Minerva Ginecol; 2019 Jun; 71(3):182-190. PubMed ID: 30727721
[TBL] [Abstract][Full Text] [Related]
5. Topotecan and gemcitabine in platinum/paclitaxel-resistant ovarian cancer.
Greggi S; Salerno MG; D'Agostino G; Ferrandina G; Lorusso D; Manzione L; Mancuso S; Scambia G
Oncology; 2001; 60(1):19-23. PubMed ID: 11150903
[TBL] [Abstract][Full Text] [Related]
6. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR).
Sehouli J; Chekerov R; Reinthaller A; Richter R; Gonzalez-Martin A; Harter P; Woopen H; Petru E; Hanker LC; Keil E; Wimberger P; Klare P; Kurzeder C; Hilpert F; Belau AK; Zeimet A; Bover-Barcelo I; Canzler U; Mahner S; Meier W
Ann Oncol; 2016 Dec; 27(12):2236-2241. PubMed ID: 27789470
[TBL] [Abstract][Full Text] [Related]
7. Phase I dose escalation study of gemcitabine and paclitaxel plus colony-stimulating factors in previously treated patients with advanced breast and ovarian cancer.
Iaffaioli RV; Tortoriello A; Santangelo M; Turitto G; Libutti M; Benassai G; Frattolillo A; Ciccarelli PD; De Rosa P; Crovella F; Carbone I; Barbarisi A
Clin Oncol (R Coll Radiol); 2000; 12(4):251-5. PubMed ID: 11005695
[TBL] [Abstract][Full Text] [Related]
8. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
Edwards SJ; Barton S; Thurgar E; Trevor N
Health Technol Assess; 2015 Jan; 19(7):1-480. PubMed ID: 25626481
[TBL] [Abstract][Full Text] [Related]
9. A phase I trial of gemcitabine and topotecan in previously treated ovarian or peritoneal cancer: a Gynecologic Oncology Group study.
Chen MD; Fleming GF; Mitchell S; Horowitz I
Gynecol Oncol; 2006 Jan; 100(1):111-5. PubMed ID: 16150481
[TBL] [Abstract][Full Text] [Related]
10. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.
Bookman MA; Malmström H; Bolis G; Gordon A; Lissoni A; Krebs JB; Fields SZ
J Clin Oncol; 1998 Oct; 16(10):3345-52. PubMed ID: 9779711
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients.
Lund B; Hansen OP; Neijt JP; Theilade K; Hansen M
Anticancer Drugs; 1995 Dec; 6 Suppl 6():61-2. PubMed ID: 8718427
[TBL] [Abstract][Full Text] [Related]
12. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial.
Niho S; Kubota K; Goto K; Ohmatsu H; Matsumoto T; Kakinuma R; Nishiwaki Y
Cancer Chemother Pharmacol; 2003 Jul; 52(1):19-24. PubMed ID: 12712259
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer.
Herben VM; Panday VR; Richel DJ; Schellens JH; van der Vange N; Rosing H; Beusenberg FD; Hearn S; Doyle E; Beijnen JH; ten Bokkel Huinink WW
J Clin Oncol; 1999 Mar; 17(3):747-55. PubMed ID: 10071262
[TBL] [Abstract][Full Text] [Related]
14. Treatment of recurrent or persistent platinum-refractory ovarian, fallopian tube or primary peritoneal cancer with gemcitabine and topotecan: a phase II trial of the Puget Sound Oncology Consortium.
Goff BA; Holmberg LA; Veljovich D; Kurland BF;
Gynecol Oncol; 2008 Aug; 110(2):146-51. PubMed ID: 18538834
[TBL] [Abstract][Full Text] [Related]
15. Topotecan in platinum- and paclitaxel-resistant ovarian cancer.
Swisher EM; Mutch DG; Rader JS; Elbendary A; Herzog TJ
Gynecol Oncol; 1997 Sep; 66(3):480-6. PubMed ID: 9299264
[TBL] [Abstract][Full Text] [Related]
16. Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer: Safety Run-in Results of the PENELOPE Trial.
González-Martín A; Pautier P; Mahner S; Rau J; Colombo N; Ottevanger P; Del Campo JM; Selle F; du Bois A; Gadducci A; García Y; Berton-Rigaud D; Marmé F; Ortega E; Martin N; Bastiere-Truchot L; Kiermaier A; Kurzeder C
Int J Gynecol Cancer; 2016 Jun; 26(5):898-905. PubMed ID: 27206218
[TBL] [Abstract][Full Text] [Related]
17. Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.
Sehouli J; Stengel D; Oskay-Oezcelik G; Zeimet AG; Sommer H; Klare P; Stauch M; Paulenz A; Camara O; Keil E; Lichtenegger W
J Clin Oncol; 2008 Jul; 26(19):3176-82. PubMed ID: 18591555
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of gemcitabine and epirubicin for the treatment of platinum-resistant or refractory advanced ovarian cancer.
Pignata S; Varriale E; Casella G; Iodice F; De Placido G; Perrone F; Tramontana F; Ricchi P; De Vivo R; Costanzo R; Vernaglia A; Tramontana S
Ann Oncol; 2000 May; 11(5):613-6. PubMed ID: 10907958
[TBL] [Abstract][Full Text] [Related]
19. A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer.
Vergote I; Schilder RJ; Pippitt CH; Wong S; Gordon AN; Scudder S; Kridelka F; Dirix L; Leach JW; Ananda S; Nanayakkara N; Melara R; Bass MB; Litten J; Adewoye H; Wenham RM
Gynecol Oncol; 2014 Oct; 135(1):25-33. PubMed ID: 25019569
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine combined with oxaliplatin (GEMOX) as second-line chemotherapy in patients with advanced ovarian cancer refractory or resistant to platinum and taxane.
Raspagliesi F; Zanaboni F; Vecchione F; Hanozet F; Scollo P; Ditto A; Grijuela B; Fontanelli R; Solima E; Spatti G; Scibilia G; Kusamura S
Oncology; 2004; 67(5-6):376-81. PubMed ID: 15713993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
